Dr. Reddy's Launches Geodon Generic - Analyst Blog

By
A A A

Dr. Reddy's Laboratories ( RDY ) recently announced the US launch of its generic version of Pfizer Inc. 's ( PFE ) antipsychotic drug, Geodon (ziprasidone). Earlier this month, the US Food and Drug Administration (FDA) had approved Dr. Reddy's abbreviated new drug application (ANDA) for the generic drug.

Geodon is approved for the treatment of schizophrenia and bipolar disorder.

According to IMS Health, US sales of Geodon amounted to about $1.34 billion for the twelve months ended December 31, 2011.


We expect generic launches at regular intervals to add to Dr. Reddy'sGlobal Generic revenues, which soared 57% year-over-year to $402 million in the third quarter of fiscal 2012.

During the reported quarter, generics' revenues climbed 133% in North America, 15% in Russia and other CIS (Commonwealth of Independent States) markets, 14% in Europe and 11% in India. Growth was mainly driven by the launch of a generic version of Eli Lilly & Co. 's ( LLY ) Zyprexa (olanzapine) 20 mg.

Dr. Reddy's currently has 180-day marketing exclusivity for Zyprexa. Therefore, since generic Zyprexa was launched in the third quarter of fiscal 2012, the exclusivity runs till the fourth quarter of fiscal 2012.

Our Take

We currently have a Neutral recommendation on Dr. Reddy's. The stock carries a Zacks #2 Rank (Buy rating) in the short-run. We believe Dr. Reddy's is in a strong position to benefit from the huge potential presented by the US generics market, as quite a few blockbuster drugs such as Johnson & Johnson 's ( JNJ ) Concerta and Pfizer's Lipitor have lost patent exclusivity and more drugs are slated to go off-patent in the coming years.


 
JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report
 
LILLY ELI & CO ( LLY ): Free Stock Analysis Report
 
PFIZER INC ( PFE ): Free Stock Analysis Report
 
DOCTOR REDDYS ( RDY ): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: JNJ , LLY , PFE , RDY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Don't Pay Up to Play REITs
Don't Pay Up to Play REITs          

Stocks

Referenced

Most Active by Volume

100,376,898
  • $17.62 ▲ 0.51%
83,231,837
  • $25.62 ▲ 1.91%
75,739,329
  • $111.78 ▼ 0.77%
65,297,937
  • $36.37 ▼ 1.76%
59,053,093
  • $47.66 ▲ 0.29%
53,482,350
  • $2.59 ▼ 0.38%
51,504,284
  • $7.34 ▲ 2.37%
51,434,656
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com